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Abstract
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MicroRNAs are a class of small regulatory RNAs that function to modulate protein expression.
This control allows for fine-tuning of the cellular phenotype, including regulation of proliferation,
cell signaling, and apoptosis; not surprisingly, microRNAs contribute to liver cancer biology.
Recent investigations in human liver cancers and tumor-derived cell lines have demonstrated
decreased or increased expression of particular microRNAs in hepatobiliary cancer cells. Based on
predicted and validated protein targets as well as functional consequences of altered expression,
microRNAs with decreased expression in liver tumor cells may normally aid in limiting neoplastic
transformation. Conversely, selected microRNAs that are upregulated in liver tumor cells can
promote malignant features, contributing to carcinogenesis. In addition, microRNAs themselves
are subject to regulated expression, including regulation by tumor suppressor and oncogene
pathways. This review will focus on the expression and function of cancer-related microRNAs,
including their intimate involvement in tumor suppressor and oncogene signaling networks
relevant to hepatobiliary neoplasia.
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Overview of MicroRNA Expression and Function
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The description and regulation of microRNA biogenesis has been extensively reviewed (1–
3) and will be addressed here briefly (Figure 1A). Transcription of microRNA genes is
under control of promoter elements regulated by established transcription factors, such as cMyc (4,5). This regulation of expression may provide for a clinically useful point of
intervention, either by stimulating a microRNA whose expression is inappropriately
suppressed or by inhibiting expression of an amplified microRNA.
The primary transcript is cleaved by the endonuclease-containing microprocessor complex
in the nucleus to yield the precursor microRNA. Of note, increased processing of the mir-21
primary transcript by TGF-ȕ induced SMAD activity has recently been described in vascular
smooth muscle cells (6). Surprisingly, the mechanism is through the non-canonical action of
SMAD binding to the RNA helicase p68 rather than transcriptional activation (Figure 1A). It
remains to be seen if SMAD-assisted processing contributes to mir-21 overexpression in
hepatobiliary cancers, or if SMAD increases processing of other primary microRNAs. The
precursor microRNA is then exported from the nucleus and cleaved in the cytoplasm by
Dicer and the mature microRNA is incorporated into the RNA-induced silencing complex
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(RISC) by the RISC-loading complex. The resulting microRNA-loaded RISC contains a
single-stranded 19–23 nucleotide microRNA that guides sequence-specific translational
suppression.
Silencing of microRNA targets is directed by base-pairing of the microRNA to the cognate
messenger RNA, specifically at the microRNA “seed” nucleotides 2–7 (Figure 1B),
augmented by neighboring nucleotides. Thus, microRNAs can have dozens to hundreds of
targets (7, 8). Quantitative proteomic analysis of microRNA targets has recently been
employed (7, 8), and confirmed the multitude of targets for several microRNAs. Further,
based on the modest protein silencing observed in these studies, microRNAs may act to finetune protein expression rather than acting as an all-or-none switch. Conversely, it should
also be noted that multiple microRNAs may cooperatively target the same mRNA resulting
in stimulus- and context-specific microRNA inhibition of protein expression. In addition to
the majority of studies indicating microRNA mediated suppression of protein expression,
recent reports also describe increased expression of targets by microRNAs (9, 10).

MicroRNAs in Cancer Biology
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Significant efforts to describe microRNA expression in cancer have yielded a wealth of data,
and a few notable trends. It is generally, though not universally, observed that microRNA
expression levels are decreased in cancer compared to non-tumor tissue. This may be
attributable to a broad suppression of microRNA expression by cancer associated
transcription factors. For example, c-Myc suppresses expression of greater than 10
microRNAs in two B-cell lymphoma models (5). Alternatively, in cancer cell lines,
precursor microRNAs were present in the nucleus but the mature form was absent from the
cytoplasm, including liver tissue and hepatocellular carcinoma (HCC) samples (11). This
suggests post-transcriptional regulation, presumably by altered processing or transport,
though accelerated degradation of the mature microRNA remains a possibility. In a rat
model of induced HCC, mir-122 expression was decreased, a finding also observed in 50%
of human tumor samples (12). In HCC, an array-based analysis identified 44 microRNAs
that were expressed at lower levels in HCC compared to normal livers (13). A separate study
comparing HCC to liver cirrhosis demonstrated dowregulation of 34 microRNAs and
increased expression of only one microRNA in HCC (14). Common to these analyses is
decreased expression of the liver specific microRNA, mir-122, as well as mir-199. Other
microRNAs demonstrating decreased expression in HCC include family members of let-7,
mir-125, mir-150, mir-195, and mir-200 (15–20). In contrast, there are a handful of
microRNAs that exhibit increased expression in tumors. Specific examples in liver cancer
include mir-21 and the mir-17–92 cluster (12,13,16,18,21,22), with mir-17–92 expression
increasing with progressive de-differentiation in HCC (15).
Based on the above information, it is clear a large number of targets are regulated by
microRNAs. How these microRNAs regulate critical pathways of hepatobiliary cancer
development and progression, represents a useful framework for understanding microRNAs
and cancer.

Targeting Tumor Suppressors
Tumor suppressors are often lost through genetic or epigenetic mechanisms, but silencing
through microRNA targeting may also be important. For instance, phosphatase and tensin
homolog deleted on chromosome 10 (PTEN) is a tumor suppressor that counters
phosphatidylinositol-3 kinase (PI3K) activation. PI3K stimulates AKT resulting in a survival
signal, thus PTEN silencing allows PI3K/AKT activation and inappropriate survival of
cancer cells. In addition, PTEN causes decreased nuclear cyclin D1 levels and cell cycle
arrest in G1. Loss of PTEN, therefore, allows unchecked cell cycle progression. Importantly,
Hepatology. Author manuscript; available in PMC 2010 August 1.
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PTEN has been identified in cholangiocarcinoma (23) and HCC (13) as a target for mir-21,
frequently upregulated in cancer.

NIH-PA Author Manuscript

Transforming growth factor-beta (TGF-ȕ) has a complicated role in cancer, acting initially
as a tumor suppressor but after malignant transformation promoting proliferation and
survival. The TGF-ȕ signaling pathway phosphorylates and activates SMAD transcription
factors, which in turn promote expression of the cyclin-dependent kinase inhibitor p21/Cip1
and downregulate c-Myc expression. In addition, ligation of the TGF-ȕ receptor promotes
phosphorylation of death-associated protein 6 (DAXX), which then activates JNK,
promoting apoptosis (24). Thus, decreased TGF-ȕ signaling can permit cell proliferation and
limit apoptosis. It is of significant interest, then, that mir-21 targets the TGF-ȕ pathway at
multiple steps. Specifically, in glioblastoma cells, mir-21 targets the TGF-ȕ receptors
TGFBR2 and TGFBR3 as well as DAXX; increased or decreased mir-21 levels have
reciprocal effects on TGFRB2, TGFRB3, and Daxx. In addition, mir-21 inhibition also
permits increased expression of the ligands TGFB1 and TGFB2 and SMAD3 at the mRNA
level (25).
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While estrogen signaling can promote carcinogenesis in some tissues, it acts as a tumor
suppressor for HCC, contributing to the lower HCC incidence in women. Estrogen receptorĮ has been identified as a target for mir-18a in HCC, and mir-18a (a mir-17–92 cluster
microRNA) was expressed at higher levels specifically in women with HCC. Transfection
with mir-18a increased proliferation and decreased the estrogen-mediated transcriptional
response in HCC cells (26). Thus, in some patients, mir-18a overexpression may defeat the
protective effects of estrogen by silencing receptor expression.
The retinoblastoma family of proteins (Rb1, p107, and Rbl2/p130) binds E2F transcription
factors blocking entry into the cell cycle. Downregulation of retinoblastoma releases E2F
which promotes proliferation. Retinoblastoma proteins have been shown to be important in
hepatobiliary cancers (27,28) and represent possible targets for post-transcriptional gene
silencing. Of note, in lung, colon, and breast cancer, expression of the mir-17–92-related
mir-106 has an inverse expression to Rb1 (29) and in the lung, retinoblastoma 2 (Rbl2/p130)
(30,31) was silenced by the mir-17–92 cluster. The specific role of mir-17–92 targeting of
retinoblastoma proteins in HCC or cholangiocarcinoma remains to be demonstrated, but is
likely.
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Interestingly, while E2F proteins drive mir-17–92 expression, mir-17–92 also targets E2F
proteins. For instance, in HepG2 cells, a mix of antisense oligonucleotides to mir-17–92 led
to increased E2F1 (protein) and E2F3 (mRNA) expression (21). As mir-17–92 is often
increased in cancer (including HCC and cholangiocarcinoma), mir-17–92 silencing of E2F
proteins at first seems paradoxical, given that the E2F transcription factors promote cell
cycle progression. However, excessive activity of E2F1 also causes apoptosis (32), so the
feedback inhibition of mir-17–92 on E2F proteins may allow proliferation while mitigating
apoptosis, consistent with a fine-tuning function of microRNAs. Another relevant mir-17–92
target is p21/Cip1, demonstrated in B-cell lymphoma (33) and other non-liver tumor tissues
(34). Activation of p21/Cip1 is sufficient to hold the cell at the G1/S checkpoint, thus p21/
Cip silencing may help promote proliferation. The regulation of cell division is further
altered in HCC cells by the overexpression of mir-221 in 71% of HCCs causing decreased
expression of the cyclin-dependent kinase inhibitors p57 and p27 and increasing the number
of cells in S phase (35).
In addition to dysregulated proliferation, inappropriate resistance to apoptosis is an
important feature of hepatobiliary cancers. Related to Bcl-2 by their Bcl-2 homology domain
3 (BH3) regions, BH3-only proteins are pro-apoptotic, and can act as tumor suppressors
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(36). The above-mentioned mir-17–92 cluster targets Bim expression in B cells, B cell
lymphoma, T cells, lung tissue, and gastric cancer (33,37–40); thus mir-17–92 may act
through multiple pathways to promote proliferation and stifle apoptosis (Figure 2). The role
of mir-17–92 silencing of Bim in liver cancers remains to be defined. Mice deficient in
Dicer manifest increased Bim protein expression and apoptosis likely due in part to loss of
Bim suppression by mir-17–92 (37). By extension, the finding of increased hepatocyte
apoptosis in mice with liver-specific Dicer deletion (41) would be consistent with
microRNA regulation of a proapoptotic protein, such as Bim, in hepatocytes, but requires
further investigation.
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A tumor suppressor of significant interest is p53, a protein lost or mutated in over half of all
human cancers. Recently, mir-29 family members were found to upregulate p53 expression
in non-liver cancer cell lines indirectly through PI3K (42). The role of p53 or PI3K
regulation by microRNAs in hepatobiliary cancer is unknown, though mir-29 is expressed at
lower levels in malignant cholangiocarcinoma cells (43). Indirectly, mir-21 is thought to
inhibit the p53 pathway without affecting p53 levels, though the mechanism is not known
(25,44). Alternately, activation of p53 induces expression of mir-34 in multiple cell types,
including a murine model of hepatocellular carcinoma (45), silencing genes involved in cell
cycle progression as well as apoptosis (46). It is possible then that loss of p53 function fails
to stimulate mir-34 expression, allowing unchecked proliferation and survival. Consistently,
mir-34a was decreased in 76% of HCC patients, all of which had mutated p53 (47). The role
of mir-34 in liver cancer deserves further clarification, as mir-34a was detected in HCC but
not normal tissue by microRNA array (48), and expressed at a higher level in HCC cell
lines, while mir-34c was decreased in HBV-positive compared to HCV-positive patients
(49), and a murine model of induced HCC manifests decreased mir-34a levels (17).
Correlation of mir-34 expression with p53 status may help refine this issue (47).

Allowing Oncogene Expression
The common finding of lower microRNA expression in cancerous tissue suggests that
microRNA targets normally kept in check may be released in tumor cells. In lung tumors,
let-7 was found to suppress the proto-oncogene Ras (50). In addition, transfection of a colon
cancer cell line with let-7 suppressed not only Ras, but also c-Myc expression (51). The
decreased expression of let-7 in many cancers may allow Ras and c-Myc overexpression.
Although let-7 expression in HCC and cholangiocarcinoma is not always suppressed
(13,48), let-7 has been described to be downregulated in HCC compared to cirrhotic liver
(14).
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Overexpression of mir-34 may have therapeutic value in HCC and cholangiocarcinoma.
mir-34 has been shown to regulate the antiapoptotic protein Bcl-2, N-Myc (52), and the
receptor tyrosine kinase c-Met (45,47). Finally, cyclin E2 (CCNE2) and cyclin-dependent
kinase 4 (CDK4) are additional targets that may allow proliferation when mir-34 expression
is low (45). Thus overexpression of mir-34 may be expected to have a beneficial effect in
liver cancers by decreasing proliferation through targeting of N-Myc, CDK4, CCNE2, and
c-Met as well as increasing apoptosis through targeting Bcl-2.
Mcl-1, Bcl-2, Bcl-w and other related proteins inappropriately block cancer cell apoptosis
and are known to be targeted by microRNAs. Mcl-1 is frequently overexpressed in HCC and
cholangiocarcinoma and is a known target of mir-29b (43) and mir-320 (22) in
cholangiocarcinoma cells, and mir-101 in HCC (53). Restoring mir-29b expression in
cholangiocarcinoma cells sensitizes to apoptosis, and antagonism of mir-29b in nonmalignant cells allowed Mcl-1 protein overexpression and apoptosis resistance. Similarly,
transfection with mir-320 or mir-101 sensitized cells to apoptosis induction (22,53). Bcl-2 is
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likewise a target for mir-204 in cholangiocarcinoma cells (22). The dominant microRNA in
the liver is mir-122 (54), which is lower in HCC samples (12,14), so it is of interest that
mir-122 targets Bcl-w (55). Bcl-w is predominantly expressed in testicular tissue, and so a
role in HCC may be unexpected. However, with downregulation of mir-122, it is not
unreasonable to speculate that Bcl-w may be expressed ectopically due to relief of
repression. Restoring mir-122 expression in HepG2 and Hep3B cells targeted Bcl-w mRNA
and protein expression and there were 25–35% fewer cells and 2- to 2.5-fold increased
Caspase-3 activity 72 hours after mir-122 transfection (55). The reduced cell number after
72 hours may be due to an increase in cell death, or alternatively through decreased
proliferation, potentially due to mir-122 silencing of cyclin G1 (14). Proliferation may also
be increased through overexpression of Stathmin, a microtubule regulatory protein that is a
target of mir-223, which was decreased in HCC (56), or through the concerted effects on cMet, FoxP1, and HDAC4 by mir-1-1 which is suppressed by CpG methylation in HCC (57).
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Another pathway commonly activated in HCC is Wnt signaling. Wnt family ligands bind
their receptor (frizzled) resulting in inhibition of glycogen synthase kinase 3ȕ (GSK3ȕ).
GSK3ȕ phosphorylates ȕ-catenin causing degradation, thus inhibition of GSK3ȕ leads to
accumulation and transcriptional activity of ȕ-catenin, including transcription of cyclin D1.
Recently, it was demonstrated that mir-141, mir-200a, ᙐ200b, ᙐ200c, and mir-429 inhibited
Wnt/ȕ-catenin signaling. Further investigation of this microRNA family in Wnt/ȕ-catenin
signaling is warranted. Potential intersection with the TGF-ȕ signaling pathway exists here,
as mir-200a/b/c, mir-141, and mir-429 are all downregulated by TGF-ȕ (58).

Altered MicroRNA Expression
MicroRNA expression is regulated at multiple levels, including transcriptional and posttranscriptional controls. While TGF-ȕ/SMAD signaling is important in preventing
tumorigenesis, paradoxically, tumor cells have enlisted this pathway to their advantage, and
often show activation of TGF-ȕ/SMAD signaling. It is then an important finding that
receptor-associated SMAD proteins promote expression of mir-21. The mechanism involves
a novel association of SMAD1/5 with the microprocessor complex, specifically the p68
helicase in the nucleus demonstrated in pulmonary artery smooth muscle cells. This
association promotes processing of the mir-21 primary transcript (and possibly primir-199a), promoting increased mature mir-21 (see Figure 1) (6). Additionally, TGF-ȕ
signaling was found to increase expression of the clustered mir-23a, mir-27a, and mir-24 in
HCC cell lines, and expression of this cluster was increased in human HCC tumor tissue.
The authors also showed that mir-24 and mir-27a increased cell number and an antagonist of
mir-27a increased caspase 3/7 activity after TGF-ȕ treatment (59).
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In the liver, inflammation plays a significant role in carcinogenesis, including the
stimulatory effect of IL-6 as a mitogen and pro-survival factor in cancer cells. In addition to
transcriptional effects, IL-6 also can modulate gene expression by increasing expression of
DNA methyl transferase-1. In cholangiocarcinoma, IL-6 silenced expression of 7
microRNAs that were increased by an inhibitor of DNA methylation (miR-99a, miR-122a,
miR-145, miR-182, miR-198, miR-291-5p, and miR-370; (60)). Indeed, methylation appears
to regulate expression of many microRNAs (61). In the liver, decreased expression of
mir-1-1 in HCC samples was found to be due to CpG methylation of exon 1 and intron 1 of
the mir-1-1 gene (57).
The oncogenic effect of viral infection of hepatocytes likely includes the local inflammatory
reaction, chronically increased hepatocyte proliferation, the cirrhotic environment, as well as
insertional effects in the case of hepatitis B virus (HBV). Samples from cirrhotic, virally
infected livers compared to non-cirrhotic, non-infected samples showed increased
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expression of a host of microRNAs, including mir-221, ᙐ222, ᙐ23b, let-7a and let-7d (18).
The same study showed altered expression of 16 microRNAs in HCC, including increased
expression of the mir-17–92 family member mir-18, mir-21, and mir-221 as well as
decreased expression of mir-101, mir-199 family members, and mir-223. Nineteen
microRNAs correlated with patient survival, with low expression in the group with poor
survival, including let-7 (ᙐ7c and ᙐ7g) mir-29c and mir-221.
Molecular mechanisms causing dysregulated microRNA expression in the liver due to
genomic alteration have been described, including chromosomal rearrangement in virallyinfected cells and single-nucleotide polymorphism. The woodchuck hepatitis virus (WHV)
is a hepadnavirus similar to HBV, and an unusual chromosomal break was described in a
WHV-associated cancer in which the 5’ end of hcr (the gene encoding mir-122) was
translocated to the c-Myc locus, inducing a 50-fold increase in c-Myc expression (62),
presumably due to expression of c-Myc by the mir-122 promoter. The mir-122 gene that was
severed from its promoter lost expression, as mir-122 levels in this cell were reportedly
reduced (63). A separate study described a G to C single nucleotide polymorphism in the
stem-loop of the mir-146a precursor sequence associated with HCC in males (GG
genotype), and the G allele was processed more efficiently to mature mir-146a. Transfection
of cells with mir-146a, mimicking the presumed higher expression in GG patients, increased
cell proliferation and colony formation of NIH/3T3 cells (64).
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Implications for Hepatobiliary Cancers
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HCC and cholangiocarcinoma each commonly arise under conditions of inflammation and
ongoing cellular injury, providing an environment rich in cytokines and chemokines that can
be hostile to cell survival. Thus, two prominent features of hepatobiliary cancers are
increased proliferation (even in pre-malignant phases) and resistance to apoptosis.
Prominent signaling pathways important for carcinogenesis in the liver include TGF-ȕ/
SMAD, PI3K/AKT/mTOR, Ras/MAPK , Wnt/ȕ-catenin, and hepatocyte growth factor/cMet. In HCC, molecular classification of tumors reveals subgroups with activated Wnt/ȕcatenin signaling distinct from receptor tyrosine kinases. Thus, elevated mir-21 and mir-17–
92 expression may contribute to hepatobiliary cancer development (18,21,56), potentially
through regulation of TGF-ȕ/SMAD. Likewise, PTEN negatively regulates PI3K/AKT/
mTOR signaling and mir-21 mediated suppression of PTEN in cholangiocarcinoma and
HCC has been demonstrated (13,23). The negative regulation of Wnt signaling by the
mir-200 family may be especially important in HCC where mir-200 and the related mir-141
are frequently expressed at lower levels in HCC (14,15,17,18). The potential role of Ras
overexpression in response to decreased let-7 in liver cancer requires further investigation.
Figure 2 illustrates validated microRNA targets in hepatobiliary cancers.
The altered profile of microRNAs in hepatobiliary neoplasia offers an opportunity clinically,
as microRNA levels may aid in diagnosis, prognosis, and treatment. The diagnostic potential
includes using microRNA expression as a marker to distinguish tumor from non-tumor (16),
as well as a serum, bile, or stool marker of occult disease. For cholangiocarcinoma, the need
for a tumor marker is apparent, given the low yield of cytology in malignant biliary
strictures due to the desmoplastic nature of bile duct cancers (65). The prognostic utility of
microRNA expression may lie in empiric associations with molecular, pathologic, or clinical
features (16,19). Ultimately, a mechanistic understanding of microRNA function may
provide a better link between expression and prognosis. The therapeutic promise of this
class of regulators rests in the broad ability of individual microRNAs to shape the cellular
phenotype. Therapy directed individually at apoptosis, angiogenesis, proliferation, or
metastasis carries a likelihood of treatment resistance. However, targeting one or a few
microRNAs may allow a concerted assault on several or all of these features of malignancy.
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Delivery of microRNAs to the tumor remains a significant challenge, but may not be
prohibitive because microRNAs are endogenously expressed. Targeting expression or
processing with small molecule inhibitors may allow therapeutic management of microRNA
expression and bypass the limitations of gene therapy. Contemplation of affecting
microRNA regulation toward a therapeutic goal will depend on understanding the relevant
protein targets of that microRNA.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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RISC

RNA-induced silencing complex

HCC

hepatocellular carcinoma

PTEN

phosphatase and tensin homolog deleted on chromosome 10

PI3K

phosphatidylinositol-3 kinase

TGF- ȕ

transforming growth factor- ȕ

DAXX

death-associated protein 6

Rb1

retinoblastoma 1

Rbl2/p130

retinoblastoma-like 2

BH3

Bcl-2 homology domain 3

CCNE2

cyclin E2

CDK4

cyclin-dependent kinase 4

GSK3 ȕ

glycogen synthase kinase 3ȕ
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Figure 1. MicroRNA Expression and Processing
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(A) MicroRNAs are expressed as primary transcripts and processed by the microprocessor
in the nucleus to precursor microRNAs. For the TGF-ȕ responsive mir-21 and mir-199a,
interaction of SMAD proteins with the p68 helicase in the microprocessor increases
processing to the precursor, facilitating expression via processing. The precursor is exported
for subsequent cleavage by Dicer in the cytoplasm. The mature microRNA is loaded into the
RISC complex and suppresses translation of target mRNAs. (B) The mature microRNA is
19–23 nucleotides in length, with the specificity-determining seed region (nucleotides 2–7)
at the 5’ end. MicroRNA family members generally share an identical seed and differ at
only a few positions overall (underlined). The mir-17–92 cluster is illustrated, demonstrating
the seed (bold) as well as the high degree of similarity of family members (mir-17 and
mir-20a). Note that the mir-18 sequence is similar to mir-17 and mir-20a but has a different
seed sequence, indicating a different set of targets.
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Figure 2. MicroRNAs Involved in Proliferation and Apoptosis

MicroRNAs commonly overexpressed in hepatobiliary cancer, such as mir-17–92 and
mir-21 (black boxes), target proteins involved in apoptosis (yellow) and inhibiting cell
proliferation (light yellow). In addition, E2F proteins have pleiotropic effects on
proliferation and apoptosis. MicroRNAs with lower expression in hepatobiliary cancer
(white boxes) target proteins that drive proliferation (light blue) or promote survival (blue).
The effect is that in general, oncogenes are released and tumor suppressors silenced by
microRNA dysregulation in cancer.
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